What are analysts'target prices for cytek Biosciences'stock?
4 Wall Street analysts have issued 1-year target prices for Cytek BioSciences' stock. Their forecasts range from $17.00 to $28.00. On average, they anticipate Cytek BioSciences' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 97.0% from the stock's current price.
Who are cytek Biosciences'(CytK) shareholders?
Top institutional shareholders include Miura Global Management LLC (2.26%), BlackRock Inc. (1.77%), Geode Capital Management LLC (0.27%), State Street Corp (0.20%), Northern Trust Corp (0.12%) and Renaissance Technologies LLC (0.08%). Company insiders that own Cytek BioSciences stock include Ming Yan, Ra Capital Management, LP and Wenbin Jiang.
Is cytek's hammer chart pattern time for bottom fishing?
Cytek Biosciences, Inc. (CTKB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Cytek Biosciences, Inc. (CTKB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
Is CTKB stock a buy right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 1 hold ra...
Will Cytek Biosciences' stock price go up in 2022?
3 brokerages have issued 1-year price objectives for Cytek Biosciences' shares. Their forecasts range from $12.00 to $18.00. On average, they expec...
How has Cytek Biosciences' stock price performed in 2022?
Cytek Biosciences' stock was trading at $16.32 at the beginning of 2022. Since then, CTKB shares have decreased by 33.4% and is now trading at $10....
When is Cytek Biosciences' next earnings date?
Cytek Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, September 1st 2022. View our earnings forecast for...
How were Cytek Biosciences' earnings last quarter?
Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.02) earnings per share...
What guidance has Cytek Biosciences issued on next quarter's earnings?
Cytek Biosciences updated its FY 2022 earnings guidance on Wednesday, June, 8th. The company provided EPS guidance of for the period. The company i...
Who are Cytek Biosciences' key executives?
Cytek Biosciences' management team includes the following people: Dr. Wenbin Jiang Ph.D. , Pres, CEO & Chairman (Age 58, Pay $568.5k) Mr. Patrik...
Who are some of Cytek Biosciences' key competitors?
Some companies that are related to Cytek Biosciences include 10x Genomics (TXG) , HORIBA (HRIBF) , Olink Holding AB (publ) (OLK) , Pacific Bios...
When did Cytek Biosciences IPO?
(CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00...
Is Cytek Biosciences stock a Buy, Sell or Hold?
Cytek Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 5 buy ratings, 3 hold ratings, and 0 se...
What was the 52-week low for Cytek Biosciences stock?
For Cytek Biosciences stock is no 52WeekLow data available or the value couldn't be calculated because of a value to close/at 0.00.
What was the 52-week high for Cytek Biosciences stock?
For Cytek Biosciences stock is no 52WeekHigh data available or the value couldn't be calculated because of a value to close/at 0.00.
What are analysts forecasts for Cytek Biosciences stock?
The 8 analysts offering price forecasts for Cytek Biosciences have a median target of 18.63, with a high estimate of 28.00 and a low estimate of 11...
About Cytek BioSciences
Headlines
Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.
Cytek BioSciences (NASDAQ:CTKB) Frequently Asked Questions
Should Cytek Biosciences, Inc. (NASDAQ:CTKB) Focus On Improving This Fundamental Metric?
Transparency is our policy. Learn how it impacts everything we do
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytek BioSciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cytek BioSciences stock. View analyst ratings for Cytek BioSciences or view top-rated stocks.
How we make money
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
How we use your personal data
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
How we approach editorial content
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
